CVT12011965
Crohn's Disease
Pre-clinicalActive
Key Facts
About CVasThera
CVasThera is a Paris-based, privately-held biotech founded in 2016 by seasoned pharmaceutical executives. It operates as a project accelerator, identifying and developing small molecule drug candidates, primarily in cardiovascular and gastrointestinal diseases, through a model built on expert guidance, funding access, and strategic intellectual property management. The company's pipeline includes partnered and internal programs at pre-clinical stages, supported by research grants and collaborations with academic and industry partners. Its core value proposition is de-risking and accelerating early-stage biopharmaceutical projects for partners and its own portfolio.
View full company profileTherapeutic Areas
Other Crohn's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Repositioned/Rerouted API | Reponex | Not Specified |
| PALI-2108 | Palisade Bio | Preclinical |
| TRX319 | Tr1X | Phase 1/2a |
| Budesonide capsules, 3mg | Sciecure Pharma | Approved |
| EXL01 | Exeliom Biosciences | Phase 2 |
| StroMel™ (Planned) | Akan Biosciences | Planned |
| omilancor | NImmune Biopharma | Phase 2 |
| SyqeAir Inhaler – Crohn's Disease | Syqe Medical | Commercial |
| Obefazimod (ABX464) | Abivax | Phase 3 |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Phase 2/3 |
| VTX002 | Ventyx Biosciences | Phase 2 |